Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.
- Cortes, Javier
- Vahdat, L.
- Blum, J.
- Twelves, Chris J
- Campone, M.
- Roche, Henri
- Bachelot, Thomas
- Awada, Ahmad
- Paridaens, R.
- Goncalves, A.
- Shuster, D.
- Wanders, Jantien
- Fang, F.
- Gurnani, R.
- Richmond, E.
- Cole, Patricia E
- Ashworth, Simon
- Allison, M.
Publication date
September 2010
DOI Publisher
American Society of Clinical Oncology (ASCO) ISSN
0732-183XAbstract
The activity and safety of eribulin mesylate (E7389), a nontaxane microtubule dynamics inhibitor with a novel mechanism of action, were evaluated in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, taxane, and capecitabine.Clinical Trial, Phase IIJournal ArticleMulticenter StudyResearch Support, Non-U.S. Gov'tinfo:eu-repo/semantics/publishe
Add to ORKG